Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunocore Holdings Plc ADR
(NQ:
IMCR
)
32.12
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immunocore Holdings Plc ADR
< Previous
1
2
3
4
5
6
Next >
Biotech's Drug Pipeline Expands From Melanoma To Other Cancers
February 13, 2023
Immunocore is the IBD Stock of the Day as the biotech company expands its pipeline. Earnings For IMCR stock are due in March.
Via
Investor's Business Daily
Is Biotech Immunocore About To Make A 25% Price Move?
February 07, 2023
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.
Via
MarketBeat
Topics
ETFs
Immunocore to present at upcoming investor conferences
February 01, 2023
From
Immunocore Holdings Limited
Via
GlobeNewswire
3 Pharma Stocks That Will Mint Millionaires
January 30, 2023
These pharma stocks all have excellent risk-reward ratios and the companies have developed treatments that could easily become blockbusters.
Via
InvestorPlace
Immunocore announces strategic priorities including pipeline expansion for 2023 -2024
January 09, 2023
From
Immunocore Holdings Limited
Via
GlobeNewswire
Analyst Ratings for Immunocore Hldgs
November 30, 2022
Via
Benzinga
Where Immunocore Hldgs Stands With Analysts
November 30, 2022
Via
Benzinga
7 Analysts Have This to Say About Immunocore Hldgs
November 30, 2022
Via
Benzinga
Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Immunocore Holdings Limited
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2022
December 16, 2022
Via
Benzinga
Where Immunocore Hldgs Stands With Analysts
November 10, 2022
Immunocore Hldgs (NASDAQ:IMCR) has observed the following analyst ratings within the last quarter:
Via
Benzinga
What 6 Analyst Ratings Have To Say About Immunocore Hldgs
October 13, 2022
Analysts have provided the following ratings for Immunocore Hldgs (NASDAQ:IMCR) within the last quarter:
Via
Benzinga
Immunocore is awarded the Prix Galien France award for KIMMTRAK
December 15, 2022
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
December 08, 2022
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
December 02, 2022
From
Immunocore Holdings Limited
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2022
November 30, 2022
Via
Benzinga
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference
November 23, 2022
From
Immunocore Holdings Limited
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
November 21, 2022
During Monday's session, 50 stocks hit new 52-week highs.
Via
Benzinga
5 Analysts Have This to Say About Immunocore Hldgs
September 14, 2022
Within the last quarter, Immunocore Hldgs (NASDAQ:IMCR) has observed the following analyst ratings:
Via
Benzinga
Procter & Gamble To Jump Over 16%? Here Are 5 Other Price Target Changes For Monday
November 21, 2022
Via
Benzinga
After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade
November 18, 2022
Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust.
Via
Benzinga
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
November 11, 2022
From
Immunocore Holdings Limited
Via
GlobeNewswire
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
November 11, 2022
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
Via
MarketBeat
Immunocore to present at the Jefferies London Healthcare Conference
November 10, 2022
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update
November 09, 2022
From
Immunocore Holdings Limited
Via
GlobeNewswire
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
September 09, 2022
Via
Benzinga
Dow Climbs More Than 400 Points, S&P 500 Rises 1.5%
September 09, 2022
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 400 points on Friday.
Via
Benzinga
Why Immunocore Shares Dipped 22%; Here Are 73 Biggest Movers From Friday
September 12, 2022
Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares climbed 71.9% to close at $2.20 on Friday after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in...
Via
Benzinga
Stocks Extend Gains, Weekly Wins In Sight
September 09, 2022
Stocks are extending this morning's gains, with the Dow Jones Industrial Average last seen up 317 points.
Via
Talk Markets
Analyzing Immunocore Hldgs's Short Interest
September 09, 2022
Immunocore Hldgs's (NASDAQ:IMCR) short percent of float has fallen 15.71% since its last report. The company recently reported that it has 902 thousand shares sold short, which is...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.